raloxifene hydrochloride has been researched along with lasofoxifene in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (36.36) | 29.6817 |
| 2010's | 14 (63.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bischoff, SF; Buhl, T; Floersheim, P; Fournier, B; Halleux, C; Kallen, J; Keller, H; Renaud, J; Schlaeppi, JM; Stark, W | 1 |
| Gajdos, C; Jordan, VC | 1 |
| Adrian, MD; Bryant, HU; Calley, JN; Chen, P; Dodge, JA; Dow, ER; Estrem, ST; Geiser, AG; Grese, TA; Halladay, DL; Helvering, LM; Huang, S; Jones, SA; Ma, YL; Miles, RR; Onyia, JE; Sato, M; Wei, T | 1 |
| Armamento-Villareal, R; Brodt, MD; Caruso, PL; Civelli, M; Civitelli, R; Galbiati, E; Halstead, LR; Mueller, C; Napoli, N; Nawaz, A; Sheikh, S; Silva, MJ | 1 |
| Crabtree, JS; Harris, HA; Komm, BS; Peano, BJ; Winneker, RC | 1 |
| de Villiers, TJ | 1 |
| Lewiecki, EM | 1 |
| Bodine, PV; Chang, KC; Komm, BS; Nagpal, S; Wang, Y | 1 |
| Becker, C | 1 |
| Biserni, A; Caruso, D; Ciana, P; Horner, D; Komm, B; Maggi, A; Ramachandran, B; Rando, G | 1 |
| Vogel, VG | 1 |
| Schmidt, C | 1 |
| Archer, DF | 1 |
| Arun, B; Brown, PH; Castiglione, M; Cuzick, J; DeCensi, A; Dunn, B; Forbes, JF; Glaus, A; Howell, A; Vogel, V; von Minckwitz, G; Zwierzina, H | 1 |
| Palacios, S | 1 |
| Hadji, P | 1 |
| Cuzick, J; Sestak, I | 1 |
| Pinkerton, JV; Stanczyk, FZ | 1 |
| Pinkerton, JV; Thomas, S | 1 |
| Andersson, A; Börjesson, AE; Carlsten, H; Farman, HH; Gustafsson, JÅ; Lagerquist, MK; Movérare-Skrtic, S; Ohlsson, C; Sjögren, K; Stubelius, A; Windahl, SH | 1 |
| Briarava, M; Mocellin, S; Nitti, D; Pilati, P | 1 |
8 review(s) available for raloxifene hydrochloride and lasofoxifene
| Article | Year |
|---|---|
Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade.
Topics: Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cinnamates; Drug Design; Forecasting; Humans; Molecular Biology; Piperidines; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Stilbenes; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Toremifene; Treatment Outcome | 2002 |
Clinical issues regarding cardiovascular disease and selective estrogen receptor modulators in postmenopausal women.
Topics: Cardiovascular Diseases; Female; Humans; Indoles; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Stroke; Tamoxifen; Tetrahydronaphthalenes; Venous Thromboembolism | 2009 |
Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Drug Therapy, Combination; Female; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Piperidines; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; RANK Ligand; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Vitamin D; Women's Health | 2009 |
Preventive therapy for breast cancer: a consensus statement.
Topics: Anastrozole; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Consensus Development Conferences as Topic; Diphosphonates; Estrogen Receptor Modulators; Expert Testimony; Female; Fenretinide; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metformin; Nitriles; Norpregnenes; Piperidines; Premenopause; Pyrrolidines; Raloxifene Hydrochloride; Retinoids; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Triazoles | 2011 |
The evolution of selective estrogen receptor modulators in osteoporosis therapy.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Endometrial Neoplasms; Female; Fractures, Bone; Hot Flashes; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Tetrahydronaphthalenes | 2012 |
Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy.
Topics: Atrophy; Estrogens; Estrogens, Conjugated (USP); Female; Humans; Indoles; Pelvic Organ Prolapse; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Treatment Outcome; Vagina; Vaginal Diseases; Vulva; Vulvar Diseases | 2014 |
Use of SERMs for treatment in postmenopausal women.
Topics: Breast Neoplasms; Clinical Trials as Topic; Dyspareunia; Estrogens, Conjugated (USP); Female; Hot Flashes; Humans; Indoles; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Toremifene | 2014 |
Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials.
Topics: Adult; Aged; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Middle Aged; Norpregnenes; Piperidines; Postmenopause; Primary Prevention; Pyrrolidines; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes | 2016 |
14 other study(ies) available for raloxifene hydrochloride and lasofoxifene
| Article | Year |
|---|---|
Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.
Topics: Administration, Oral; Animals; Binding Sites; Biological Availability; Cell Division; Crystallography, X-Ray; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; HeLa Cells; Humans; Isoquinolines; Ligands; Models, Molecular; Radioligand Assay; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Stereoisomerism; Structure-Activity Relationship; Transcription, Genetic; Tumor Cells, Cultured | 2003 |
Differential effects of estrogen and raloxifene on messenger RNA and matrix metalloproteinase 2 activity in the rat uterus.
Topics: Animals; Estrogens; Female; Gene Expression; Gene Expression Profiling; Matrix Metalloproteinase 2; Matrix Metalloproteinase 7; Oligonucleotide Array Sequence Analysis; Ovariectomy; Pyrrolidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; RNA, Messenger; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Uterus | 2005 |
A new selective estrogen receptor modulator, CHF 4227.01, preserves bone mass and microarchitecture in ovariectomized rats.
Topics: Absorptiometry, Photon; Amino Acids; Animals; Benzopyrans; Biomechanical Phenomena; Blood; Body Composition; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Cholesterol; Compressive Strength; Estrogen Receptor Modulators; Ethinyl Estradiol; Female; Femur; Femur Neck; Lumbar Vertebrae; Organ Size; Osteoclasts; Osteogenesis; Ovariectomy; Piperidines; Pyrrolidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Tetrahydronaphthalenes; Tibia; Tomography, X-Ray Computed; Triglycerides; Uterus; Weight-Bearing | 2005 |
Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland.
Topics: Amphiregulin; Animals; Dose-Response Relationship, Drug; EGF Family of Proteins; Estrogens, Conjugated (USP); Female; Glycoproteins; Indoles; Intercellular Signaling Peptides and Proteins; Mammary Glands, Animal; Mice; Mice, Inbred C57BL; Organ Size; Polymerase Chain Reaction; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Uterus | 2009 |
Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Down-Regulation; Estradiol; Estrogen Antagonists; Estrogens, Conjugated (USP); Female; Gene Expression; Gene Expression Profiling; Humans; Indoles; Oligonucleotide Array Sequence Analysis; Pyrrolidines; Raloxifene Hydrochloride; Reverse Transcriptase Polymerase Chain Reaction; Selective Estrogen Receptor Modulators; Signal Transduction; Tetrahydronaphthalenes; Up-Regulation | 2010 |
Lasofoxifene: new drug. Osteoporosis: no better than raloxifene.
Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Europe; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Tetrahydronaphthalenes | 2009 |
Another selective estrogen-receptor modulator for osteoporosis.
Topics: Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Stroke; Tamoxifen; Tetrahydronaphthalenes; Venous Thromboembolism | 2010 |
An innovative method to classify SERMs based on the dynamics of estrogen receptor transcriptional activity in living animals.
Topics: Animals; Blotting, Western; Estradiol; Estrogens, Conjugated (USP); Female; Indoles; Mice; Mice, Inbred C57BL; Ovariectomy; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Transcription, Genetic | 2010 |
Tipping the balance for the primary prevention of breast cancer.
Topics: Adult; Age Factors; Aged; Anticarcinogenic Agents; Biomarkers, Tumor; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Confounding Factors, Epidemiologic; Estradiol; Female; Fractures, Bone; Humans; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Primary Prevention; Pyrrolidines; Raloxifene Hydrochloride; Risk Assessment; Sample Size; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Treatment Outcome | 2010 |
Third-generation SERMs may face uphill battle.
Topics: Anticarcinogenic Agents; Bone Density Conservation Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Approval; Drug Industry; Estradiol; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Indoles; Osteoporosis, Postmenopausal; Patents as Topic; Primary Prevention; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; United States; United States Food and Drug Administration | 2010 |
The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women.
Topics: Breast Neoplasms; Estrogen Antagonists; Estrogens; Female; Female Urogenital Diseases; Humans; Indoles; Osteoporosis, Postmenopausal; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes | 2011 |
Selective estrogen receptor modulators: the future in menopausal treatment.
Topics: Female; Forecasting; Humans; Indoles; Menopause; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes | 2011 |
Preventive therapy for breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Endometrial Neoplasms; Female; Humans; Meta-Analysis as Topic; Middle Aged; Piperidines; Preventive Medicine; Pyrrolidines; Raloxifene Hydrochloride; Receptor, ErbB-2; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes | 2012 |
The estrogen receptor antagonist ICI 182,780 can act both as an agonist and an inverse agonist when estrogen receptor α AF-2 is modified.
Topics: Adipose Tissue; Animals; Bone and Bones; Bone Marrow Cells; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Insulin-Like Growth Factor I; Ligands; Mice; Mutation; Organ Size; Protein Structure, Tertiary; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Tetrahydronaphthalenes; Thymus Gland; Tissue Distribution; Tomography, X-Ray Computed; Uterus; X-Ray Microtomography | 2014 |